US appeals court confirms patent validity of Acadia's Parkinson's drug
The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories.
The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date.
"We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams.
This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies.
The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Global Mass Spectrometry Market to Reach USD 9.62 Billion by 2030 Amid Rising Pharmaceutical R&D, Environmental Testing, and AI-Powered Advancements: MarkNtel Advisors
NEW DELHI, Aug. 20, 2025 /PRNewswire/ -- The Global Mass Spectrometry Market size valued at approximately USD 6.9 billion in 2024, is projected to reach USD 10.38 billion by 2030, growing at a CAGR of around 7.04% during the forecast period from 2025 to 2030, according to MarkNtel Advisors. This market growth is driven by heightened concerns for public and environmental health, leading to increased food testing and sample testing. The rapid expansion of the pharmaceutical industry and the integration of AI in mass spectrometers are also pivotal. Various governments are significantly investing in mass spectrometry infrastructure, while hospitals and labs upgrade their medical devices with advanced systems. However, challenges like high operational costs and a shortage of trained professionals persist, especially in remote areas. Overall, these factors create ample growth opportunities for stakeholders in the evolving landscape of analytical techniques, biotechnology innovation, and healthcare quality control. Mass Spectrometry Market Report Scope: Study Period: 2025-2030 Growth Rate (CAGR): 7.04% During 2025-30 Market Size (2024): USD 6.9 Billion Market Value (2030): USD 10.38 Billion Leading Region: North America Interested User Can Get a FREE sample of the report here: Top Mass Spectrometry Manufacturers/Companies Worldwide The Mass Spectrometry Global Market is seeing dynamic activity from top mass spectrometry manufacturers/companies aiming to expand their market share. Key players like Thermo Fisher Scientific Inc., Agilent Technologies Inc., and Waters Corporation are leading the way, alongside Danaher Corporation, Bruker Corporation, and Shimadzu Corporation. Companies such as PerkinElmer Inc., JEOL Ltd., LECO Corporation, and Advion Inc. are actively pursuing mergers, collaborations, and acquisitions to enhance their competitive advantage. Their focus on innovation, research and development, and diverse product portfolios positions them for sustained growth in an evolving industry. With a commitment to improving operational efficiency and addressing market demands, these firms are shaping the future of analytical instruments and driving revenue growth in the mass spectrometry sector. Rising Demand Across Key Sectors Mass spectrometry has become a cornerstone technology for high-precision analytical testing, enabling industries to identify, quantify, and characterize chemical compounds with unmatched accuracy. The surge in adoption is driven by multiple high-growth sectors: Pharmaceuticals & Biotechnology: Increased spending on drug discovery, diagnostics, and biomarker identification is fueling demand. LC-MS and hybrid spectrometers are now essential for nitrosamine impurity testing, compliance with FDA and EMA regulations, and advanced proteomics research. Environmental Testing: With growing concerns around PFAS, microplastics, and nitrosamines, mass spectrometry is emerging as the go-to tool for regulatory bodies such as the U.S. EPA, which has approved LC-MS/MS protocols (Methods 533 & 537.1) for drinking water testing. Food & Beverage Safety: Rising global emphasis on quality assurance (QA) protocols, contaminant detection, and chemical residue analysis is creating new demand for advanced MS solutions. Energy & Climate Research: Mass spectrometers are being deployed for climate modeling, energy exploration, and environmental monitoring, aligning with sustainable development goals. Market Dynamics: Key Drivers Emerging Contaminants Testing: The rapid evolution of contaminants like PFAS, nitrosamines, and microplastics has made mass spectrometry indispensable for compliance and research. Growing Pharma R&D Budgets: With double-digit YOY increases in pharmaceutical R&D spending, mass spectrometry is becoming central to both drug discovery and quality control (QC) processes. Government Regulations: Stringent drug safety protocols, environmental monitoring standards, and food safety laws are pushing adoption globally. Access Complete Data Tables, Forecasts, Segment, and Competitor Profiles Here: Growth Restraints High Cost of Systems: Instruments range from USD 75,000 to USD 500,000 depending on type and configuration, with GC-MS averaging USD 50,000–115,000 and single-mass systems priced at USD 350,000–400,000. Operational & Training Costs: In addition to capital investment, users face maintenance, calibration, reagent, and skilled labor costs. Smaller labs face difficulties due to infrastructure limitations. Skilled Workforce Shortage: Efficient MS usage requires specialized training in sample preparation, method development, and troubleshooting. With only four researchers per 10,000 workers in India and a projected 65,000 bio-economy professionals needed in Canada by 2029, the talent gap could slow adoption. Opportunities Technological Advancements: Breakthroughs in AI integration, machine learning, mass spectrometry imaging (MSI), high-resolution MS (HRMS), and miniaturized portable MS devices are broadening applications across healthcare, forensic science, and diagnostics. OMICS Revolution: Growth in proteomics, genomics, and metabolomics is creating opportunities in personalized medicine, diabetes research, and congenital disorder screening. Portable Solutions: Field-deployable MS systems now allow real-time on-site diagnostics in environmental testing, agriculture, and border security. Future Trends: The global mass spectrometry market is witnessing a significant trend with the integration of artificial intelligence in mass spectrometers. This innovation enhances the efficiency of these medical devices, allowing for faster and more accurate results compared to traditional methods that require manual analysis. Companies like Agilent, Thermo Fisher, Bruker, and Waters are leading the charge in manufacturing AI-enabled mass spectrometers. For example, Thermo Fisher Scientific launched the Orbital Astral Zoom MS in 2025, which utilizes AI software via the Ardia platform for improved multiplexing and scanning speeds. Agilent Technologies also introduced the InfinityLab Pro iQ series in 2025, featuring AI-powered compact Liquid Chromatography-Mass Spectrometry (LC-MS). This system autonomously detects faults and suggests corrections, showcasing how AI advancements are effectively transforming the mass spectrometry landscape. Global Mass Spectrometry Market Segmentation Analysis: By Product Type: Based on mass spectrometry product type segment market is led by instruments, particularly hybrid mass spectrometers. These devices combine different mass analyzers, enhancing sensitivity and accuracy. Their ability to generate complex data quickly drives widespread adoption and necessitates software for data management. By Application: The OMICS research segment is projected to grow notably in mass spectrometry. Its applications in diagnostics and biomarker identification, particularly in biopharma and genomics, are driving advancement, especially in diabetes and newborn screening. By End User: The pharmaceutical sector is expected to see the fastest growth in mass spectrometry. Increased regulations in drug manufacturing and advancements in QC processes are pushing pharmaceutical companies to adopt mass spectrometers, solidifying their dominant position in the market. Regional Insights: North America Leading Growth North America South America Europe The Middle East & Africa Asia-Pacific North America leads the mass spectrometry market, holding a 38% share, thanks to its robust pharmaceutical and biotech sectors. Key companies like Pfizer, Johnson & Johnson, and Merck in the U.S., along with Canada's Apotex, drive innovation in drug discovery and testing. Significant government and private funding for R&D, such as grants from the National Institutes of Health and the Canada Foundation for Innovation, further bolster the region's market position. These investments highlight North America's prominent role in advancing mass spectrometry technology. Request Your Custom Global Mass Spectrometry Market Report – Regional or Country Specific – Get tailored insights for your exact target market. Related Questions You May Find Helpful: Q1: How big is the global mass spectrometry market? The market was USD 6.33 billion in 2024 and is projected to reach USD 9.62 billion by 2030 at a 7.2% CAGR, driven by pharma R&D, food safety testing, and environmental monitoring. Q2: How expensive is a mass spectrometer? Costs range from USD 75,000 to USD 500,000. GC-MS averages USD 50,000–115,000, while advanced hybrid and high-resolution systems exceed USD 400,000. Q3: What are the latest advancements in mass spectrometry market? In 2025, Agilent Technologies Inc. introduced the InfinityLab Pro iQ Series, which includes the Pro iQ and Pro iQ Plus LC–MS detectors designed for quicker, smarter, and more automated laboratory processes. Alongside, they upgraded the 8850 GC system for compatibility with mass spectrometry. These innovations are smaller, faster, and more eco-friendly, earning certification from My Green Lab for sustainability. Q4: What are the future trends of mass spectrometry? Integration of artificial intelligence with MS devices is one of the key trends shaping the growth of the Mass Spectrometry Market. Q5: What are the downsides of mass spectrometry? Challenges include high upfront costs, ongoing consumable expenses, complex operation, infrastructure needs, and a global shortage of skilled analysts. Q6: What is the difference between MS, MS/MS, and LC-MS? MS identifies compounds by mass-to-charge ratio. MS/MS (tandem MS) provides deeper structural data using two analyzers. LC-MS couples liquid chromatography with MS for separating complex mixtures before analysis. Q7: How is mass spectrometry used in the pharmaceutical industry? Pharma companies rely on MS for drug discovery, nitrosamine impurity profiling, biologics QC, biomarker validation, and regulatory compliance testing. Q8: Do hospitals and clinical labs use mass spectrometry? Yes. Hospitals use MS for toxicology, newborn screening, infectious disease biomarker testing, therapeutic drug monitoring, and personalized medicine diagnostics. Q9: What is the difference between NMR and MS? NMR uses magnetic resonance to analyze molecular structure. MS determines mass-to-charge ratios for chemical identification and are complementary in drug development and biomolecular research. Q10: Who are the leaders and manufacturers in the mass spectrometry market? Key players include Agilent, Thermo Fisher, Danaher (SCIEX), Waters, Bruker, Shimadzu, PerkinElmer, JEOL, and Hitachi High-Tech. Q11: Why are spectrometers so expensive? They require precision engineering, high-tech detectors, proprietary software, costly consumables, and rigorous calibration standards, which increase price. Q12: What industries will drive future MS adoption? Growth will be strongest in pharma & biotech, food & beverage safety, environmental testing, clinical diagnostics, energy/petrochemicals, and forensic sciences. MarkNtel Blogs: Key Players Boosting Japan Anime Merchandising Industry Growth - Top AV Cable Companies Driving Residential Connectivity in South Korea - Top Companies in Japan Wax Industry - India Sports Nutrition Top Brands to Watch in 2025 - Top Companies Operating in Online Gaming Market - Key Brands in India Bath Soap Market - Top 10 Electric Vehicle Companies in India 2025: From Startups to Auto Giants- Top 7 ATM Companies Shaping the Global Market Landscape - Top Pan Masala Brands in India - About Us MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others. We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others. Logo: Contact Us:MarkNtel AdvisorsOffice No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, IndiaContact No: +91 8719999009Email: sales@ Visit our Website: Content Source: View original content: SOURCE MarkNtel Advisors
Business Insider
29 minutes ago
- Business Insider
Link11 Highlights Growing Cybersecurity Risks and Introduces Integrated WAAP Protection Platform
Frankfurt am Main, Germany, August 20th, 2025, CyberNewsWire Link11, a Germany-based global IT security provider, has released insights into the evolving cybersecurity threat landscape and announced the capabilities of its Web Application and API Protection (WAAP) platform, designed to provide multi-layered defenses against modern digital threats. The rapid pace of digital transformation has expanded the opportunities for organizations across industries. However, every new web application and API also broadens the attack surface, leaving businesses increasingly exposed. Cybercriminals are employing sophisticated tactics that target all levels of application infrastructure, rendering traditional point solutions insufficient. Key Threats Facing Digital Platforms: Distributed denial-of-service (DDoS) attacks have traditionally been associated with overwhelming data floods. Increasingly, attackers use more subtle methods at the application level (Layer 7), simulating legitimate traffic to disrupt resource-intensive services such as login pages, search functions, or APIs. A recent example occurred when the website of an Israeli city council was hit by approximately 18 million HTTP requests in just minutes, temporarily disrupting operations. Malicious bots Automated traffic continues to account for a significant share of web activity, with malicious bots responsible for credential stuffing, content scraping, inventory theft, and fraud. Reseller bots, for example, often purchase large volumes of limited products such as concert tickets or designer items, leaving genuine customers unable to access them. Limitations of traditional WAFs Web Application Firewalls (WAFs) remain widely used but often rely on signature-based rules, which can fail to detect newer attack methods while generating false positives. Such gaps leave applications vulnerable to modern 'low-and-slow' attacks and zero-day exploits, as well as to familiar threats like SQL injection or cross-site scripting (XSS). API vulnerabilities APIs are central to digital ecosystems, yet frequently underprotected. Unmonitored 'shadow APIs' can unintentionally expand the attack surface. Attacks on API endpoints can lead to service disruptions, data theft, and account takeovers, underscoring the need for more advanced defenses. The Link11 WAAP Platform Link11's WAAP platform has been developed to address these challenges through an integrated, real-time security framework. Unified all-in-one platform: Consolidates multiple protection functions into a single interface to simplify management. Real-time multi-layered protection: Detects and mitigates malicious traffic while ensuring seamless access for legitimate users. Flexible deployment: Compatible with diverse infrastructures, protecting web applications and APIs regardless of hosting environment. 24/7 managed support: Backed by round-the-clock monitoring from Link11's global Security Operations Centers (SOCs). Data security and compliance: Operates on a wholly Link11-owned cloud platform, ensuring GDPR compliance and eliminating non-EU access risks. About Link11 Link11 is a specialized IT security provider headquartered in Germany with offices worldwide. The company delivers enterprise-grade cybersecurity solutions, including protection for critical infrastructures. Link11 is ISO 27001 certified and recognized by the German Federal Office for Information Security (BSI) as a qualified provider for critical infrastructure protection. Contact Link11 GmbH
Business Wire
29 minutes ago
- Business Wire
Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth
SAN FRANCISCO--(BUSINESS WIRE)--AI in revenue cycle management has become top of mind across the healthcare industry, but when it comes to the dental market, dentists are lacking the modern tools used by their medical counterparts. That's the problem that AI-powered dental RCM platform, Wisdom, is on a mission to solve. The company announced today the successful completion of its $21M Series A capital raise led by Permanent Capital Ventures (PCV), a venture capital firm that partners with founders to build go-to-market engines for enterprise scale. Aquiline, a private investment firm specializing in financial services and technology, joined the round, alongside existing investor and Co-Founder, Juxtapose, a leading creation-oriented investment firm. Juxtapose followed their recent $7M Seed investment, reaffirming the firm's commitment to Wisdom's continued growth and innovation. This funding brings Wisdom's total capital raised to $28M since its founding in 2023. The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Share The overwhelming majority of independent practices and small dental groups in America struggle with the administrative burden of running a profitable business, leaving over $20 billion of earned revenue uncollected despite spending billions of dollars on salaries for in-house revenue management. Wisdom, which has already collected hundreds of millions of dollars for its clients and saved them up to 50% of collection costs, takes a highly differentiated approach to administrative workflows by bringing AI agents and human experts together to maximize revenue collections, predictability, transparency and patient satisfaction, thereby freeing dentists and their staff to focus on delivering outstanding patient care. Since its inception, Wisdom has rapidly expanded by combining advanced, proprietary AI-driven technology with US-based billing experts. This unique approach has propelled Wisdom to achieve exceptional client satisfaction, underscored by a consistently high Net Promoter Score of 73 and strong organic growth. Over 50% of Wisdom's signed deals still come through referrals. Wisdom was awarded Top Dental Billing Company by Healthcare Business Review earlier this year and was named a 2025 Dental Innovator Award winner by DentalIQ for its AI-assisted dental billing service. Wisdom is led by CEO Stoyan Kenderov, an accomplished technologist, product leader and executive with over 25 years of success building new products and transforming organizations into customer-obsessed teams that drive growth and profitability, most recently as COO of business payments platform Plastiq. Prior to his time at Plastiq, Stoyan held senior leadership roles at LendingClub, Intuit, Quicken, and many other international technology companies. Stoyan is joined by Wisdom Co-Founder and Chief Dental Billing Officer Ashley Bond, who previously founded and led the award-winning nationwide billing service, Bond Dental Billing. 'We are thrilled to partner with PCV and Aquiline as we continue our mission to transform dental billing and revenue management,' said Kenderov. 'Their proactive approach and expertise in building scalable enterprises align perfectly with our vision to significantly enhance financial outcomes and operational efficiency for dental practices.' PCV's investment in Wisdom reflects the firm's strategy of supporting innovative startups poised for transformational growth. 'Wisdom has created an impressive track record by uniquely integrating AI technologies with deep industry expertise,' said Mike Gamson, Co-Founder and Managing Partner at Permanent Capital Ventures. 'We see immense potential in their ability to scale and redefine revenue management solutions in the dental sector and beyond.' Aquiline has a history of building scaled revenue cycle management businesses, and this investment in Wisdom marks the firm's second investment supporting the dental industry. 'While we continue to see significant innovation across dental, the market is filled with point solutions and generally lacks modern, end-to-end platforms, especially across the rev cycle process,' said Dante La Ruffa, Partner at Aquiline. 'We believe that Stoyan and his team are reimagining the future of dentistry, starting with the key pain points that have historically inhibited dentists from maximizing their time with patients.' This funding will enable Wisdom to further enhance its technology platform, accelerate market expansion, and continue building out its exceptional team to better serve dental offices of all sizes - from private practices to multi-location dental groups across the country. 'The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Stoyan and his team have moved quickly but thoughtfully to build a solution which really moves the needle for dentists while preserving the value of human expertise,' said Andy Stein, Partner at Juxtapose. For more information about Wisdom and its innovative dental billing solutions, please visit About Juxtapose Juxtapose is a creation-oriented investment firm building and funding industry-defining technology companies. Juxtapose's concept development and investment process is focused on multi-decade opportunities in complex industries that leverage the team's expertise in software and technology, human-centered design, commercial strategy, executive talent assessment, and private capital markets. Juxtapose has built and led the financing of companies across software, healthcare, and tech-enabled services that have raised over $1B of external, follow-on private capital. Founded in 2016, Juxtapose now has over $1B AUM. About Permanent Capital Ventures Permanent Capital Ventures is an expansion stage venture capital firm that partners with extraordinary founders building AI application businesses. We lean in with unique go-to-market expertise in the moments after product-market fit has been established to help unlock the path to enterprise scale. About Aquiline Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management across the firm's three strategies in private equity, venture, and credit. Additional information is available on the firm's website: Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management and has deployed approximately $7.4 billion of capital across the firm's three strategies in private equity, venture, and credit.
